^
    18h
    Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors (clinicaltrials.gov)
    P1/2, N=64, Suspended, National Cancer Institute (NCI) | Trial completion date: Dec 2026 --> Dec 2027 | Recruiting --> Suspended | Trial primary completion date: Feb 2026 --> Dec 2026
    Trial completion date • Trial suspension • Trial primary completion date
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    temozolomide • vincristine • locnartecan (PEN-866)
    1d
    Epithelioid and spindle cell rhabdomyosarcoma of the rib with FUS-TFCP2 fusion: A case report and literature review. (PubMed, Oncol Lett)
    The patient succumbed to the disease 4 months after surgery. RMS with FUS-TFCP2 fusion is rare, highly aggressive and associated with a poor prognosis.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • FUS (FUS RNA Binding Protein) • TFCP2 (Transcription Factor CP2) • MYOD1 (Myogenic Differentiation 1)
    |
    CDKN2A deletion
    1d
    Rare primary pleomorphic rhabdomyosarcoma of the thyroid gland with lung and adrenal metastases: a case report and literature review. (PubMed, Front Oncol)
    After four cycles of chemotherapy, the patient achieved partial regression of metastatic lesions. The highly aggressive nature of PRMS emphasizes the importance of having individualized and multidisciplinary treatment approaches to such rare cases.
    Journal
    |
    VIM (Vimentin)
    2d
    Diffusion Weighted Magnetic Resonance in Imaging Younger Patients With Newly Diagnosed Bone or Soft Tissue Sarcomas (clinicaltrials.gov)
    P=N/A, N=98, Completed, St. Jude Children's Research Hospital | Active, not recruiting --> Completed
    Trial completion
    2d
    Pediatric inflammatory myofibroblastic tumor of the urinary bladder: a rare case report and treatment approach. (PubMed, Turk J Pediatr)
    Partial cystectomy was performed, but due to positive surgical margins and recurrent hematuria, targeted therapy with crizotinib was initiated based on anaplastic lymphoma kinase (ALK) positivity...This case highlights the importance of a multidisciplinary approach involving surgery, pathology, and oncology. Further pediatric-focused studies are warranted to refine treatment strategies and define long-term outcomes.
    Journal
    |
    ALK (Anaplastic lymphoma kinase)
    |
    Xalkori (crizotinib)
    7d
    Cytological, Immunocytochemical and Molecular Findings of Extraskeletal Round Cell Sarcomas in Paediatric Patients. (PubMed, Acta Cytol)
    Key messages Round cell sarcomas share many morphological similarities, so the differential diagnosis can be broad; however, subtle differences between tumours can aid the final diagnosis. Nevertheless, most round cell sarcomas require molecular studies for accurate classification, and cytological specimens are usually high quality material for such ancillary techniques.
    Review • Journal
    |
    BCOR (BCL6 Corepressor) • EWSR1 (EWS RNA Binding Protein 1)
    8d
    Adult liver rhabdomyosarcoma complicated with sarcomatoid carcinoma: A case report. (PubMed, World J Gastrointest Oncol)
    By sharing the diagnosis and treatment process of this patient and reviewing the relevant literature, we aim to help clinicians enhance their understanding of two rare diseases, namely pleomorphic RMS and sarcomatoid carcinoma of the liver.
    Journal • IO biomarker
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • AFP (Alpha-fetoprotein)
    |
    MET amplification
    |
    doxorubicin hydrochloride • cyclophosphamide • vincristine
    9d
    PROSARC-1: Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma (clinicaltrials.gov)
    P2, N=110, Recruiting, Oslo University Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    9d
    PROSARC-2: Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma. (clinicaltrials.gov)
    P2, N=40, Recruiting, Oslo University Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    10d
    Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE) (clinicaltrials.gov)
    P1, N=18, Recruiting, Children's National Research Institute | Not yet recruiting --> Recruiting | Initiation date: Oct 2025 --> Jan 2026
    Enrollment open • Trial initiation date
    |
    cyclophosphamide
    11d
    Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma (clinicaltrials.gov)
    P2, N=59, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed | Trial completion date: Feb 2026 --> Feb 2025
    Trial completion • Trial completion date
    |
    gemcitabine • albumin-bound paclitaxel
    11d
    A scientometric and comparative study of rhabdomyosarcoma research by pediatricians and stomatologists. (PubMed, J Dent Sci)
    Cancer chemotherapy mainly vincristine, dactinomycin, and cyclophosphamide, surgery, radiotherapy, and brachytherapy were the common keywords of treatment. The more common keywords such as age, facial neoplasms, mouth neoplasms, orbital neoplasms, gingiva, mandible, DNA-binding proteins, gene silencing, and Rh30 cell line were reported by stomatologists. This study is the first comprehensive report of the scientometric characteristics of RMS publications by pediatricians and stomatologists, highlighting the need for increased awareness among clinicians to avoid diagnostic delays and ensure timely treatment.
    Journal
    |
    FOXO1 (Forkhead box O1) • PAX3 (Paired Box 3)
    |
    cyclophosphamide • vincristine • dactinomycin